drugset
drugset / Trial / NCT02002208

Effect of OC000459 on Moderate to Severe Atopic Dermatitis

NCT02002208 ↗

Phase 2 Completed 142 enrolled Atopix Therapeutics, Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether OC000459 is in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (AD).

Timeline

Start
2013-10
Primary completion
2015-09
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject TIMAPIPRANT Small molecule 50 mg Oral

Indications

atopic eczema